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The triterpene gossypol competes with bilirubin for a high-affinity binding site on human serum albumin. 
Similar competition between bilirubin and gossypol occurs in the binding of these ligands to the 
glutathione S-transferases from human liver and placenta. In each case, gossypol and bilirubin exhibit 
similar binding constants. The binding properties of gossypol may generally mimic those of bilirubin. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Recent reports from the People’s Republic of 
China on the antifertility properties of gossypol 
have prompted a renewed interest in this abundant 
polyphenolic triterpene obtained from cottonseed 
oil [l]. Clinical trials in China suggest that 
gossypol is an effective, non-steroidal, antifertility 
drug for men [2,3]. In addition, reports have ap- 
peared recently on the potential usefulness of 
gossypol as a drug against herpes simplex virus [4], 
Chagas disease [5] and malaria [6]. In view of the 
potential broad spectrum activity of gossypol as a 
drug, knowledge of the transport and metabolism 
of gossypol will be useful. In general, it appears 
from studies with a variety of animals that 
gossypol is metabolized primarily in the liver where 
glucuronides and sulfate esters of gossypol are pro- 
duced and subsequently excreted into the bile [7]. 
There are no data on the mode of transport of 
gossypol in the circulation or in the liver. Here, we 
demonstrate that gossypol binds to a high-affinity 
binding site on human serum albumin with an af- 
finity comparable to that for the binding of 
bilirubin. 
Bilirubin, gossypol-acetic acid (scheme 1) and 
human serum albumin were obtained from Sigma. 
Stock solutions of bilirubin were prepared fresh in 
0.1 M KOH and kept in the dark. Stock solutions 
of gossypol were prepared in 95% ethanol. The 
binding of gossypol to albumin was determined by 
following the quenching of the intrinsic protein 
fluorescence upon addition of gossypol; pH 7.4, 
0.02 M potassium phosphate, 0.1 M NaCl, 25”C, 
A,, = 280 mn, hem = 320 nm, slits = 3 nm. The 
binding of bilirubin to albumin and subsequent 
displacement of the bilirubin by gossypol was 
followed by circular dichroism, using the same 
buffer system as was used in the fluorescence 
studies. 
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3. RESULTS 
3.1. Fluorescence titration of the binding of 
gossypol to human serum albumin 
Human serum albumin contains a single tryp- 
tophan residue, located in domain II IS]. The 
fluorescence emission spectrum of albumin, due 
mainly to tryptophan emission, overlaps with the 
absorption spectrum of gossypol. The addition of 
gossypol to solutions of albumin results in quen- 
ching of the intrinsic fluorescence, as shown in 
fig. 1, when gossypol was added to 1 pM albumin. 
Quenching of the fluorescence is essentially 
stoichiometric for the first equivalent of gossypol, 
suggesting that binding is taking place at a high- 
affinity site. 
3.2. Competition between bilirubin and gossypol 
for binding to human serum albumin 
Fig.2 (curve a) shows the circular dichroic spec- 
trum of the bil~ubin-~bu~n complex formed by 
treating 50pM albumin with one equivalent of 
bilirubin. Addition of up to 5 equivalents of 
gossypol to this solution results in a progressive 
displacement of bilirubin, as monitored by loss of 
the circular dichroic spectrum. The complex of 
gossypol and albumin produces a very weak spec- 
trum which does not interfere. Three equivalents 
of gossypol can displace 50% of the bilirubin. 
Previously we determined the dissociation constant 
for bilirubin under the same experimental condi- 
tions used in the present study, & = 3 x lo-’ M 
[9]. Thus we can estimate the dissociation constant 
[Gossypol] / [Albumin] 
Fig. 1. Fluorescence quenching of human serum albumin 
upon addition of gossypol @H 7.4) 25T; [albumin] = 
1 pM. 
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Fig.2. Circular dichroic spectrum of the 
b~lirubin-albumin complex (curve a) and displacement 
of bilirubin upon addition of l-5 equivalents of 
gossypol, pH 7.4; [albumin] = 50 PM. Ellipticities are in 
millidegrees. 
for gossypol, & = 9 x IO-* M, based upon the 
competition in fig.2. 
In order to demonstrate that gossypol displaces 
bilirubin, as suggested by the data in fig.2, 
bilirubin was added to albumin and the resulting 
mixture was treated with various amounts of 
gossypol. The free ligands were separated from 
~b~in-bound ligands by chromatography on 
Sephadex LH20. Albumin transports 3 equivalents 
of bilirubin through the column. Gossypol is able 
to displace 1 equivalent. Albumin transports 4 
equivalents of gossypol through the column. 
Bilirubin is able to displace 1 equivalent. Thus 
there is a single site where bilirubin and gossypol 
compete. The circular dichroism data suggest hat 
this is the high-affinity bilirubin-binding site. 
3.3. minding of gossypo~ to other bi~irubin- 
binding proteins 
The glutathione S-transferases from human liver 
[9] and placenta [lo] have unique bilirubin-binding 
sites. Fig.3 shows the circular dichroic spectrum of 
the bilirubin-transferase complex formed by ad- 
ding two equivalents of bilirubin to 22 ,uM placen- 
ta transferase. Gossypol can displace about 50% 
of the bilirubin when the gossypol and bilirubin 
concentrations are equal, suggesting comparable 
binding constants for bilirubin and gossypol. 
Previously, the dissociation constant for bilirubin 
was determined to be 14 PM [lo]. A similar experi- 
ment with liver transferase (not shown) again 
showed that gossypol can displace bilirubin from 
the bilirubin-transferase complex. In this case 
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Fig.3. Circular dichroic spectrum of the bilirubin 
complex with placenta glutathione S-transferase (curve 
a) and dispIacement of bilirubin by gossypol, pH 7.4. 
Two equivalents of bilirubin were added to 22/1M 
transferase, followed by addition of l-6 equivalents of 
gossypol. 
also, the binding of gossypol or bilirubin showed 
similar affinities. Thus it appears that, for a varie- 
ty of proteins which are known to bind bilirubin, 
the binding of gossypol occurs at the bilirubin- 
binding site with affinities which are similar to 
those for the binding of bilirubin. 
4. DISCUSSION 
Many drugs bind to serum albumin in competi- 
tion with bilirubin [ill. However, the binding of 
these drugs is generally not very tight compared 
with the binding of bilirubin. For example, sodium 
salicyiate shows a Kd = 1.1 x 10m4 M; most known 
drugs which compete with biiirubin show & = 
10V2 to 10m4 M [ll]. Gossypol appears to be uni- 
que compared with other drugs which can displace 
bilirubin, in that the binding of gossypol to 
albumin is almost as tight as the binding of 
bilirubin and is ld- to 105-times better than the 
binding of other drugs. The fact that this same pat- 
tern is observed with liver glutathione S- 
transferase and placenta glutathione S-transferase 
suggests that gossypol may generally mimic 
bilirubin. Gossypol should be a useful compound 
for studies of bilirubin metabolism. There remain 
many unanswered questions concerning transport, 
hepatic uptake and biliary excretion of bilirubin 
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